Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medicinova Inc (MNOV)

Medicinova Inc (MNOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,741
  • Shares Outstanding, K 49,046
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -8,570 K
  • 60-Month Beta 0.72
  • Price/Sales 64.74
  • Price/Cash Flow N/A
  • Price/Book 1.10
Trade MNOV with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 34.09%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 619.24% on 06/04/24
  • IV Low 0.00% on 07/25/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 120
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 114
  • Open Int (30-Day) 155

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.06
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 unch
on 07/25/24
1.4700 -11.56%
on 07/15/24
-0.1200 (-8.45%)
since 06/25/24
3-Month
1.2800 +1.56%
on 06/21/24
1.5500 -16.13%
on 05/10/24
-0.0200 (-1.52%)
since 04/25/24
52-Week
1.2600 +3.17%
on 02/27/24
2.5600 -49.22%
on 08/04/23
-1.0600 (-44.92%)
since 07/25/23

Most Recent Stories

More News
MediciNova: Q1 Earnings Snapshot

MediciNova: Q1 Earnings Snapshot

MNOV : 1.3000 (-1.52%)
MediciNova: Q3 Earnings Snapshot

MediciNova: Q3 Earnings Snapshot

MNOV : 1.3000 (-1.52%)
MediciNova: Q2 Earnings Snapshot

MediciNova: Q2 Earnings Snapshot

MNOV : 1.3000 (-1.52%)
MediciNova: Q1 Earnings Snapshot

MediciNova: Q1 Earnings Snapshot

MNOV : 1.3000 (-1.52%)
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

LA JOLLA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

MNOV : 1.3000 (-1.52%)
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

LA JOLLA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

MNOV : 1.3000 (-1.52%)
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

LA JOLLA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and...

MNOV : 1.3000 (-1.52%)
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and...

MNOV : 1.3000 (-1.52%)
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

LA JOLLA, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and...

MNOV : 1.3000 (-1.52%)
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and...

MNOV : 1.3000 (-1.52%)

Business Summary

MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies,...

See More

Key Turning Points

3rd Resistance Point 1.3500
2nd Resistance Point 1.3400
1st Resistance Point 1.3200
Last Price 1.3000
1st Support Level 1.2900
2nd Support Level 1.2800
3rd Support Level 1.2600

See More

52-Week High 2.5600
Fibonacci 61.8% 2.0634
Fibonacci 50% 1.9100
Fibonacci 38.2% 1.7566
Last Price 1.3000
52-Week Low 1.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar